Cancer Research and Treatment

Original Articles

Hematologic malignancy

Assessing the Efficacy of Bortezomib and Dexamethasone for Induction and Maintenance Therapy in Relapsed/Refractory Cutaneous T-Cell Lymphoma: A Phase II CISL1701/BIC Study: Yoon Seok Choi, Joonho Shim, Ka-Won Kang, Sang Eun Yoon, Jun Sik Hong, Sung Nam Lim, Ho-Young Yhim, Jung Hye Kwon, Gyeong-Won Lee, Deok-Hwan Yang, Sung Yong Oh, Ho-Jin Shin, Hyeon-Seok Eom, Dok Hyun Yoon, Hong Ghi Lee, Seong Hyun Jeong, Won Seog Kim, Seok Jin Kim; Cancer Res Treat. 2025;57(1):267-279. Published online July 16, 2024; DOI: https://doi.org/10.4143/crt.2024.479

Abstract PDF Supplementary Material PubReader ePub: Purpose
This multicenter, open-label, phase II trial evaluated the efficacy and safety of bortezomib combined with dexamethasone for the treatment of relapsed/refractory cutaneous T-cell lymphoma (CTCL) in previously treated patients across 14 institutions in South Korea.
Materials and Methods
Between September 2017 and July 2020, 29 patients with histologically confirmed CTCL received treatment, consisting of eight 4-week cycles of induction therapy followed by maintenance therapy, contingent upon response, for up to one year. The primary endpoint was the proportion of patients achieving an objective global response.
Results
Thirteen of the 29 patients (44.8%) achieved an objective global response, including two complete responses. The median progression-free survival (PFS) was 5.8 months, with responders showing a median PFS of 14.0 months. Treatment-emergent adverse events were generally mild, with a low incidence of peripheral neuropathy and hematologic toxicities. Despite the trend toward shorter PFS in patients with higher mutation burdens, genomic profiling before and after treatment showed no significant emergence of new mutations indicative of disease progression.
Conclusion
This study supports the use of bortezomib and dexamethasone as a viable and safe treatment option for previously treated CTCL, demonstrating substantial efficacy and manageability in adverse effects. Further research with a larger cohort is suggested to validate these findings and explore the prognostic value of mutation profiles.

1,844 View
149 Download

Lung and Thoracic cancer

The Incidence and Risk Factors of Chronic Pulmonary Infection after Radiotherapy in Patients with Lung Cancer: Yeonseok Choi, Jae Myoung Noh, Sun Hye Shin, Kyungjong Lee, Sang-Won Um, Hojoong Kim, Hongryull Pyo, Yong Chan Ahn, Byeong-Ho Jeong; Cancer Res Treat. 2023;55(3):804-813. Published online January 3, 2023; DOI: https://doi.org/10.4143/crt.2022.1305

Abstract PDF Supplementary Material PubReader ePub

Purpose
This study aimed to investigate cumulative incidence and risk factors associated with chronic pulmonary infection (CPI) development after radiotherapy for lung cancer.
Materials and Methods
We retrospectively analyzed 1,872 patients with lung cancer who received radiotherapy for lung cancer from 2010-2014, had a follow-up period of ≥ 3 months after radiotherapy, and did not have CPI at the time of radiotherapy. CPI was defined as pulmonary tuberculosis, non-tuberculous mycobacterial pulmonary disease, chronic pulmonary aspergillosis, or pulmonary actinomycosis. The cumulative incidence of CPI and overall survival (OS) were estimated using the Kaplan-Meier method, and a multivariable Cox proportional hazards analysis was performed to identify risk factors associated with CPI development.
Results
The median follow-up period was 2.3 years with OS rates of 55.6% and 37.6% at 2 and 5 years, respectively. CPI developed in 59 patients at a median of 1.8 years after radiotherapy, with cumulative incidence rates of 1.1%, 3.4%, 5.0%, and 6.8% at 1, 3, 5, and 7 years, respectively. A lower body mass index, interstitial lung disease, prior pulmonary tuberculosis, larger clinical target volume, history of lung cancer surgery or radiation pneumonitis, and use of inhaled corticosteroids were independent risk factors for CPI development.
Conclusion
The long-term survival rate of lung cancer patients receiving radiotherapy was not low, but the cumulative incidence of CPI gradually increased to 6.8% at 7 years after radiotherapy. Therefore, close monitoring of CPI development is required in surviving patients with risk factors.

Citations

Citations to this article as recorded by

Chronic progressive pulmonary aspergillosis within the irradiated field after stereotactic body radiotherapy: two case reports
Nao Mamuro, Noriko Kishi, Yukinori Matsuo, Masahiro Yoneyama, Hiroyuki Inoo, Minoru Inoue, Takashi Mizowaki
International Cancer Conference Journal.2025; 14(2): 113. CrossRef
Predictive nomogram for risk of pulmonary infection in lung cancer patients undergoing radiochemotherapy: development and performance evaluation
Yujie Huang
American Journal of Cancer Research.2025; 15(2): 781. CrossRef
The Inter-Relationships Among the Risk Factors for Pulmonary Infection and the Diagnostic Utility of Inflammatory Markers in Patients with Non-Small Cell Lung Cancer
Wenwen Qin, Tiebin You, Tai Guo, Ruixin Tian, Xiaoman Cui, Ping Wang
Infection and Drug Resistance.2025; Volume 18: 1111. CrossRef
Invasive aspergillosis complicated in a patient with non-small cell lung cancer harboring RET fusion during treatment with RET-TKIs: a case report and literature review
Kaidiriye Setiwalidi, Yimeng Li, Yuyan Ma, Zhanpeng Hao, Yujia Zhao, Yuxin Zhang, Xuan Liang, Tao Tian, Zhiping Ruan, Yu Yao, Xiao Fu
Frontiers in Oncology.2024;[Epub] CrossRef

4,614 View
191 Download
4 Web of Science
4 Crossref

Hematologic malignancy

Outcomes in Refractory Diffuse Large B-Cell Lymphoma: Results from Two Prospective Korean Cohorts: Jun Ho Yi, Seong Hyun Jeong, Seok Jin Kim, Dok Hyun Yoon, Hye Jin Kang, Youngil Koh, Jin Seok Kim, Won-Sik Lee, Deok-Hwan Yang, Young Rok Do, Min Kyoung Kim, Kwai Han Yoo, Yoon Seok Choi, Whan Jung Yun, Yong Park, Jae-Cheol Jo, Hyeon-Seok Eom, Jae-Yong Kwak, Ho-Jin Shin, Byeong Bae Park, Seong Yoon Yi, Ji-Hyun Kwon, Sung Yong Oh, Hyo Jung Kim, Byeong Seok Sohn, Jong Ho Won, Dae-Sik Hong, Ho-Sup Lee, Gyeong-Won Lee, Cheolwon Suh, Won Seog Kim; Cancer Res Treat. 2023;55(1):325-333. Published online April 22, 2022; DOI: https://doi.org/10.4143/crt.2022.008

Abstract PDF PubReader ePub

Purpose
Diffuse large B-cell lymphoma (DLBCL) is the most common hematologic malignancy worldwide. Although substantial improvement has been achieved by the frontline rituximab-based chemoimmunotherapy, up to 40%-50% of patients will eventually have relapsed or refractory disease, whose prognosis is extremely dismal.
Materials and Methods
We have carried out two prospective cohort studies that include over 1,500 DLBCL patients treated with rituximab plus CHOP (#NCT01202448 and #NCT02474550). In the current report, we describe the outcomes of refractory DLBCL patients. Patients were defined to have refractory DLBCL if they met one of the followings, not achieving at least partial response after 4 or more cycles of R-CHOP; not achieving at least partial response after 2 or more cycles of salvage therapy; progressive disease within 12 months after autologous stem cell transplantation.
Results
Among 1,581 patients, a total of 260 patients met the criteria for the refractory disease after a median time to progression of 9.1 months. The objective response rate of salvage treatment was 26.4%, and the complete response rate was 9.6%. The median overall survival (OS) was 7.5 months (95% confidence interval, 6.4 to 8.6), and the 2-year survival rate was 22.1%±2.8%. The median OS for each refractory category was not significantly different (p=0.529).
Conclusion
In line with the previous studies, the outcomes of refractory DLBCL patients were extremely poor, which necessitates novel approaches for this population.

Citations

Citations to this article as recorded by

PI3Kδ inhibitor linperlisib combined with gemcitabine and oxaliplatin for relapsed or refractory diffuse large B-cell lymphoma: a multicenter, single-arm phase Ib/II trial
Peng Sun, Hong Cen, Haiyan Yang, Rui Huang, Zhen Cai, Xuekui Gu, Hanying Bao, Zusheng Xu, Zuhong Xu, Zhi-Ming Li
Cancer Cell International.2025;[Epub] CrossRef
Improving access to chimeric antigen receptor T-cells for refractory or relapsing diffuse large B cell lymphoma therapy in Asia
Ya Hwee Tan, Dok Hyun Yoon, Andrew J. Davies, Christian Buske, Yang Liang Boo, Nagavalli Somasundaram, Francesca Lim, Shin Yeu Ong, Anand Jeyasekharan, Koji Izutsu, Won Seog Kim, Jason Yongsheng Chan
Discover Oncology.2025;[Epub] CrossRef
Recent advances in cellular immunotherapy for lymphoid malignancies
Haerim Chung, Hyunsoo Cho
Blood Research.2023; 58(4): 166. CrossRef
Sphingosine 1-phosphate receptor, a new therapeutic direction in different diseases
Hongyu Chen, Junmin Wang, Caiyun Zhang, Peilun Ding, Shuxia Tian, Junming Chen, Guang Ji, Tao Wu
Biomedicine & Pharmacotherapy.2022; 153: 113341. CrossRef

7,555 View
353 Download
3 Web of Science
4 Crossref

Pegfilgrastim Prophylaxis Is Effective in the Prevention of Febrile Neutropenia and Reduces Mortality in Patients Aged ≥ 75 Years with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Prospective Cohort Study: Seong Hyun Jeong, Seok Jin Kim, Dok Hyun Yoon, Yong Park, Hye Jin Kang, Youngil Koh, Gyeong-Won Lee, Won-Sik Lee, Deok-Hwan Yang, Young Rok Do, Min Kyoung Kim, Kwai Han Yoo, Yoon Seok Choi, Hwan Jung Yun, Jun Ho Yi, Jae-Cheol Jo, Hyeon-Seok Eom, Jae-Yong Kwak, Ho-Jin Shin, Byeong Bae Park, Shin Young Hyun, Seong Yoon Yi, Ji-Hyun Kwon, Sung Yong Oh, Hyo Jung Kim, Byeong Seok Sohn, Jong Ho Won, Se-Hyung Kim, Ho-Sup Lee, Cheolwon Suh, Won Seog Kim; Cancer Res Treat. 2022;54(4):1268-1277. Published online December 30, 2021; DOI: https://doi.org/10.4143/crt.2021.1168

Abstract PDF Supplementary Material PubReader ePub: Purpose
Febrile neutropenia (FN) can cause suboptimal treatment and treatment-related mortality (TRM) in diffuse large B-cell lymphoma (DLBCL) patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP).
Materials and methods
We conducted a prospective cohort study to evaluate the effectiveness of pegfilgrastim prophylaxis in DLBCL patients receiving R-CHOP, and we compared them with the PROCESS cohort (n=485).
Results
Since January 2015, 986 patients with DLBCL were enrolled. Pegfilgrastim was administered at least once in 930 patients (94.3%), covering 90.3% of all cycles. FN developed in 137 patients (13.9%) in this cohort (23.7% in the PROCESS cohort, p<0.001), and 4.2% of all cycles (10.2% in the PROCESS cohort, p<0.001). Dose delay was less common (≥3 days: 18.1% vs. 23.7%, p=0.015; ≥5 days: 12.0% vs. 18.3%, p=0.023) in this cohort than in the PROCESS cohort. The incidence of TRM (3.2% vs. 5.6%, p=0.047) and infection-related death (1.8% vs. 4.5%, p=0.004) was lower in this cohort than in the PROCESS cohort. The 4-year overall survival (OS) and progression-free survival (PFS) rates of the two cohorts were not different (OS: 73.0% vs. 71.9%, p=0.545; PFS: 69.5% vs. 68.8%, p=0.616). However, in patients aged ≥75 years, the 4-year OS and PFS rates were higher in this cohort than in the PROCESS cohort (OS: 49.6% vs. 33.7%, p=0.032; PFS: 44.2% vs. 30.3% p=0.047).
Conclusion
Pegfilgrastim prophylaxis is effective in the prevention of FN and infection-related death in DLBCL patients receiving R-CHOP, and it also improves OS in patients aged ≥75 years.

7,832 View
298 Download
1 Web of Science

Gynecologic Cancer

Early Metabolic Response Assessed Using ¹⁸F-FDG-PET/CT for Image-Guided Intracavitary Brachytherapy Can Better Predict Treatment Outcomes in Patients with Cervical Cancer: Nalee Kim, Won Park, Won Kyung Cho, Duk-Soo Bae, Byoung-Gie Kim, Jeong-Won Lee, Tae-Joong Kim, Chel Hun Choi, Yoo-Young Lee, Young Seok Cho; Cancer Res Treat. 2021;53(3):803-812. Published online December 9, 2020; DOI: https://doi.org/10.4143/crt.2020.1251

Abstract PDF Supplementary Material PubReader ePub

Purpose
This study aimed to identify the prognostic value of early metabolic response assessed using ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) during radiation therapy (RT) for cervical cancer.
Materials and Methods
We identified 116 patients treated with definitive RT, including FDG-PET/CT–guided intracavitary brachytherapy, between 2009 and 2018. We calculated parameters including maximum (SUV_max) and mean standardized uptake values (SUV_mean), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) for baseline FDG-PET/CT (PET_base) and image-guided brachytherapy planning FDG-PET/CT (PET_IGBT). Multivariable analyses of disease-free survival (DFS) and overall survival (OS) were performed.
Results
We observed a time-dependent decrease in PET parameters between PET_base and PET_IGBT; ΔSUV_max, ΔSUV_mean, ΔMTV, and ΔTLG were 65%, 61%, 78%, and 93%, respectively. With a median follow-up of 59.5 months, the 5-year DFS and OS rates were 66% and 79%, respectively. Multivariable analysis demonstrated that ΔSUV_max ≥ 50% was associated with favorable DFS (hazard ratio [HR], 2.56; 95% confidence interval [CI], 1.14 to 5.77) and OS (HR, 5.14; 95% CI, 1.55 to 17.01). Patients with ΔSUV_max ≥ 50% (n=87) showed better DFS and OS than those with ΔSUV_max < 50% (n=29) (DFS, 76% vs. 35%, p < 0.001; OS, 90% vs. 41%, p < 0.001, respectively). Adenocarcinoma was frequently observed in ΔSUV_max < 50% compared to ΔSUV_max ≥ 50% (27.6% vs. 10.3%, p=0.003). In addition, models incorporating metabolic parameters showed improved accuracy for predicting DFS (p=0.012) and OS (p=0.004) than models with clinicopathologic factors.
Conclusion
Changes in metabolic parameters, especially those in SUV_max by > 50%, can help improve survival outcome predictions for patients with cervical cancer treated with definitive RT.

Citations

Citations to this article as recorded by

Personalized strategies for brachytherapy of cervix cancer
Guillaume Camprodon, Alexandra Gabro, Zineb El Ayachi, Supriya Chopra, Remi Nout, Philippe Maingon, Cyrus Chargari
Cancer/Radiothérapie.2024; 28(6-7): 610. CrossRef
Brachytherapy for cervical cancer: from intracavitary to interstitial technique
Xiaojing Yang, Hanru Ren, Zhen Li, Jie Fu
Frontiers in Oncology.2024;[Epub] CrossRef
Application of three-dimensional multi-imaging combination in brachytherapy of cervical cancer
Zhaoming Zhang, Ning Zhang, Guanghui Cheng
La radiologia medica.2023; 128(5): 588. CrossRef
MRI- and PET-Based Assessment of Radiological and Clinical Factors Associated With Cervical Cancer Response to External Beam Radiation Therapy
Arun G Paul, Steven Miller, Lance K Heilbrun, Daryn W Smith
Cureus.2022;[Epub] CrossRef

6,146 View
173 Download
5 Web of Science
4 Crossref

Basic

TM4SF4 and LRRK2 Are Potential Therapeutic Targets in Lung and Breast Cancers through Outlier Analysis: Kyungsoo Jung, Joon-Seok Choi, Beom-Mo Koo, Yu Jin Kim, Ji-Young Song, Minjung Sung, Eun Sol Chang, Ka-Won Noh, Sungbin An, Mi-Sook Lee, Kyoung Song, Hannah Lee, Ryong Nam Kim, Young Kee Shin, Doo-Yi Oh, Yoon-La Choi; Cancer Res Treat. 2021;53(1):9-24. Published online September 16, 2020; DOI: https://doi.org/10.4143/crt.2020.434

Abstract PDF Supplementary Material PubReader ePub

Purpose
To find biomarkers for disease, there have been constant attempts to investigate the genes that differ from those in the disease groups. However, the values that lie outside the overall pattern of a distribution, the outliers, are frequently excluded in traditional analytical methods as they are considered to be ‘some sort of problem.’ Such outliers may have a biologic role in the disease group. Thus, this study explored new biomarker using outlier analysis, and verified the suitability of therapeutic potential of two genes (TM4SF4 and LRRK2).
Materials and Methods
Modified Tukey’s fences outlier analysis was carried out to identify new biomarkers using the public gene expression datasets. And we verified the presence of the selected biomarkers in other clinical samples via customized gene expression panels and tissue microarrays. Moreover, a siRNA-based knockdown test was performed to evaluate the impact of the biomarkers on oncogenic phenotypes.
Results
TM4SF4 in lung cancer and LRRK2 in breast cancer were chosen as candidates among the genes derived from the analysis. TM4SF4 and LRRK2 were overexpressed in the small number of samples with lung cancer (4.20%) and breast cancer (2.42%), respectively. Knockdown of TM4SF4 and LRRK2 suppressed the growth of lung and breast cancer cell lines. The LRRK2 overexpressing cell lines were more sensitive to LRRK2-IN-1 than the LRRK2 under-expressing cell lines
Conclusion
Our modified outlier-based analysis method has proved to rescue biomarkers previously missed or unnoticed by traditional analysis showing TM4SF4 and LRRK2 are novel target candidates for lung and breast cancer, respectively.

Citations

Citations to this article as recorded by

Multiomics in silico analysis identifies TM4SF4 as a cell surface target in hepatocellular carcinoma
Kah Keng Wong, Suzina Sheikh Ab. Hamid, Mahmood S Choudhery
PLOS ONE.2025; 20(2): e0307048. CrossRef
TM4SF19—A New Biomarker for Diagnosis and Prognosis of Bladder Urothelial Carcinoma
蕴博刘
Advances in Clinical Medicine.2024; 14(02): 3616. CrossRef
Validating linalool as a potential drug for breast cancer treatment based on machine learning and molecular docking
Qian Zhang, Dengfeng Chen
Drug Development Research.2024;[Epub] CrossRef
DeepDRA: Drug repurposing using multi-omics data integration with autoencoders
Taha Mohammadzadeh-Vardin, Amin Ghareyazi, Ali Gharizadeh, Karim Abbasi, Hamid R. Rabiee, Amgad Muneer
PLOS ONE.2024; 19(7): e0307649. CrossRef
TM4SF4 is a diagnostic biomarker accelerating progression of papillary thyroid cancer via AKT pathway
Lizhi Lin, Jialiang Wen, Tiansheng Xu, Yuhao Si
Cancer Biology & Therapy.2024;[Epub] CrossRef
Three Members of Transmembrane-4-Superfamily, TM4SF1, TM4SF4, and TM4SF5, as Emerging Anticancer Molecular Targets against Cancer Phenotypes and Chemoresistance
Nur Syafiqah Rahim, Yuan Seng Wu, Maw Shin Sim, Appalaraju Velaga, Srinivasa Reddy Bonam, Subash C. B. Gopinath, Vetriselvan Subramaniyan, Ker Woon Choy, Sin-Yeang Teow, Ismail M. Fareez, Chandramathi Samudi, Shamala Devi Sekaran, Mahendran Sekar, Rhanye
Pharmaceuticals.2023; 16(1): 110. CrossRef
Quantitative Analysis on Molecular Characteristics Evolution of Gastric Cancer Progression and Prognosis
Yeting Hu, Xiaoqin Lv, Wenwu Wei, Xiang Li, Kaixuan Zhang, Linlin Zhu, Tao Gan, Hongjuan Zeng, Jinlin Yang, Nini Rao
Advanced Biology.2023;[Epub] CrossRef
Study on Potential Differentially Expressed Genes in Idiopathic Pulmonary Fibrosis by Bioinformatics and Next-Generation Sequencing Data Analysis
Muttanagouda Giriyappagoudar, Basavaraj Vastrad, Rajeshwari Horakeri, Chanabasayya Vastrad
Biomedicines.2023; 11(12): 3109. CrossRef
Parkinson’s disease and cancer: a systematic review and meta-analysis on the influence of lifestyle habits, genetic variants, and gender
Joon Yan Selene Lee, Jing Han Ng, Seyed Ehsan Saffari, Eng-King Tan
Aging.2022; 14(5): 2148. CrossRef
Identification of autophagy-related biomarkers in patients with pulmonary arterial hypertension based on bioinformatics analysis
Zhisong Yang, Li Zhou, Haiyan Ge, Weimin Shen, Lin Shan
Open Medicine.2022; 17(1): 1148. CrossRef
LncRNA ST8SIA6-AS1 facilitates hepatocellular carcinoma progression by governing miR-651-5p/TM4SF4 axis
Yanjie Mou, Xiaoming Ding
Anti-Cancer Drugs.2022; 33(8): 741. CrossRef
Discovery of a potent, highly selective, and orally bioavailable inhibitor of CDK8 through a structure-based optimisation
Mingfeng Yu, Yi Long, Yuchao Yang, Manjun Li, Theodosia Teo, Benjamin Noll, Stephen Philip, Shudong Wang
European Journal of Medicinal Chemistry.2021; 218: 113391. CrossRef
Shifting Gears in Precision Oncology—Challenges and Opportunities of Integrative Data Analysis
Ka-Won Noh, Reinhard Buettner, Sebastian Klein
Biomolecules.2021; 11(9): 1310. CrossRef

11,878 View
385 Download
13 Web of Science
13 Crossref

Health-Related Quality of Life, Perceived Social Support, and Depression in Disease-Free Survivors Who Underwent Curative Surgery Only for Prostate, Kidney and Bladder Cancer: Comparison among Survivors and with the General Population: Dong Wook Shin, Hyun Sik Park, Sang Hyub Lee, Seung Hyun Jeon, Seok Cho, Seok Ho Kang, Seung Chol Park, Jong Hyock Park, Jinsung Park; Cancer Res Treat. 2019;51(1):289-299. Published online May 4, 2018; DOI: https://doi.org/10.4143/crt.2018.053

Abstract PDF PubReader ePub

Purpose
The purpose of this study was to compare health-related quality of life (HRQoL) of disease-free prostate (PC), kidney (KC), and bladder cancer (BC) survivors with that of the general population.
Materials and Methods
Our study included 331 urological cancer (UC) survivors (114 PC, 108 KC, and 109 BC) aged ≥ 50 years disease-free for at least 1 year after surgery. The control group included 1,177 subjects without a history of cancer. The HRQoL was assessed using the European Organization for Research and Treatment of Cancer QLQ-C30, the Duke-UNC Functional Social Support Questionnaire, and the Patient Health Questionnaire-9.
Results
There was no significant difference between the groups in terms of any of the functioning sub-scales and symptoms, except significantly lower social functioning observed in BC survivors than that observed in KC survivors. Although the three groups of UC survivors showed essentially similar functioning sub-scales and symptoms when compared to the general population, PC and BC survivors showed significantly lower social functioning and a lower appetite than that observed in controls. KC survivors showed lower physical functioning, as well as higher pain and dyspnea. Although all three groups of UC survivors reported higher financial difficulties, they also reported higher perceived social support than that reported by the non-cancer control group. No statistically significant difference was observed in terms of depressive symptoms between each group of UC survivors and the general population.
Conclusion
Disease-free survivors of the three major types of UCs showed generally similar HRQoL compared to the general population, as well as compared to each other.

Citations

Citations to this article as recorded by

Role performance and factors affecting quality of life in bladder cancer survivors with ileal orthotopic neobladder
So Hee Kim, Eunjung Ryu, Byong Chang Jeong
Asia-Pacific Journal of Oncology Nursing.2024; 11(6): 100490. CrossRef
The mental and emotional status after radical cystectomy and different urinary diversion orthotopic bladder substitution versus external urinary diversion after radical cystectomy: A propensity score‐matched study
Giuseppe Palermo, Francesco Pio Bizzarri, Eros Scarciglia, Emilio Sacco, Koosha Moosavi Seyed, Pierluigi Russo, Filippo Gavi, Battista Filomena Giovanni, Francesco Rossi, Marco Campetella, Angelo Totaro, Nazario Foschi, Marco Racioppi
International Journal of Urology.2024; 31(12): 1423. CrossRef
Factors Affecting the Health-Related Quality of Life of Patients with Bladder Cancer
Haetsal Kwon, Hyojung Park
Journal of Korean Public Health Nursing.2024; 38(3): 358. CrossRef
Properties of the Shift and Persist Questionnaire in adolescent and young adult cancer patients and survivors: Validity, consistency, and interpretability
Karly M. Murphy, Edith Chen, Edward H. Ip, Abby R. Rosenberg, Mallory A. Snyder, John M. Salsman
Quality of Life Research.2023; 32(1): 273. CrossRef
Adoption of patient communication rules in clinical practice and the role of faith-based communities in shaping them: the palliative aspect of spiritual support
Konstantin Sokolovskiy, Olga Pashanova, Vladimir Beketov, Andrey Aleshkin
Mental Health, Religion & Culture.2023; 26(1): 16. CrossRef
Identifying the unmet supportive care needs of people affected by kidney cancer: a systematic review
Amy O’Dea, Craig Gedye, Belinda Jago, Catherine Paterson
Journal of Cancer Survivorship.2022; 16(6): 1279. CrossRef
Mental Health in Urologic Oncology
Danyon Anderson, Abrahim N. Razzak, Matthew McDonald, David Cao, Jamal Hasoon, Omar Viswanath, Alan D. Kaye, Ivan Urits
Health Psychology Research.2022;[Epub] CrossRef
Psychological Distress in Patients Treated for Renal Cell Carcinoma: A Systematic Literature Review
Liliana Vartolomei, Manuela Schmidinger, Mihai Vartolomei, Shahrokh Shariat
Journal of Clinical Medicine.2022; 11(21): 6383. CrossRef
Health-Related Quality of Life among Cancer Survivors Depending on the Occupational Status
Kisook Kim, Hyohyeon Yoon
International Journal of Environmental Research and Public Health.2021; 18(7): 3803. CrossRef
Feasibility of a socio-spiritual intervention to improve quality of life of adult Nigerians with cancer and their family caregivers: Protocol for a randomised controlled trial
Israel Gabriel, Debra Creedy, Elisabeth Coyne
Contemporary Clinical Trials Communications.2021; 22: 100802. CrossRef
Age-specific health-related quality of life in disease-free long-term prostate cancer survivors versus male population controls—results from a population-based study
Salome Adam, Daniela Doege, Lena Koch-Gallenkamp, Melissa S. Y. Thong, Heike Bertram, Andrea Eberle, Bernd Holleczek, Ron Pritzkuleit, Mechthild Waldeyer-Sauerland, Annika Waldmann, Sylke Ruth Zeissig, Lina Jansen, Sabine Rohrmann, Hermann Brenner, Volker
Supportive Care in Cancer.2020; 28(6): 2875. CrossRef
Comorbid depression in medical diseases
Stefan M. Gold, Ole Köhler-Forsberg, Rona Moss-Morris, Anja Mehnert, J. Jaime Miranda, Monika Bullinger, Andrew Steptoe, Mary A. Whooley, Christian Otte
Nature Reviews Disease Primers.2020;[Epub] CrossRef
Health-related Quality of Life and Its Related Factors among Cancer Survivors and General Adults: Focusing on Lifestyle Behaviors and Mental Health
Eun A Song, Youngran Kweon, Yoon Young Hwang, Minjeong An
Korean Journal of Adult Nursing.2020; 32(4): 385. CrossRef
Age and gender differences in anxiety and depression in cancer patients compared with the general population
Andreas Hinz, Philipp Yorck Herzberg, Florian Lordick, Joachim Weis, Hermann Faller, Elmar Brähler, Martin Härter, Karl Wegscheider, Kristina Geue, Anja Mehnert
European Journal of Cancer Care.2019;[Epub] CrossRef

12,424 View
218 Download
12 Web of Science
14 Crossref

Oncologic and Functional Outcomes after Partial Nephrectomy Versus Radical Nephrectomy in T1b Renal Cell Carcinoma: A Multicenter, Matched Case-Control Study in Korean Patients: Hoon Ah Jang, Jin Wook Kim, Seok Soo Byun, Sung Hoo Hong, Young Jun Kim, Young Hyun Park, Kyung Suk Yang, Seok Cho, Jun Cheon, Seok Ho Kang; Cancer Res Treat. 2016;48(2):612-620. Published online June 5, 2015; DOI: https://doi.org/10.4143/crt.2014.122

Abstract PDF PubReader ePub

Purpose
The study was to compare the oncologic and functional outcomes of partial nephrectomy (PN) and radical nephrectomy (RN) for pathologically proven T1b renal cell carcinoma using pair-matched groups.
Materials and Methods
We reviewed our prospectively maintained database for RN and PN in T1b renal tumors surgically treated between 1999 and 2011 at five institutions in Korea. Of 611 patients treated with PN or RN for a solitary and NX/N0 M0 renal mass (4-7 cm), 577 (PN, 100; RN, 477) patients with pathologically confirmed pT1b remained for analysis. Study subjects were grouped by PN or RN, then matched by age, sex, comorbidities, body mass index, tumor size and depth, histologic type, and preoperative estimated glomerular filtration rate (eGFR) using propensities score. To evaluate oncologic outcomes, overall survival (OS), cancer- specific survival (CSS), and progression-free survival (PFS) rates were analyzed. The functional outcomes were evaluated by postoperative eGFR.
Results
The median follow-up in the RN group was 48.1 and 42.6 months in the PN group. The estimated 10-year CSS rate (PN 85.7% vs. RN 84.4%, p=0.52) and 5- and estimated 10-year PFS rates (PN: 86.4% and 79.2% vs. RN: 86.0% and 66.1%, p=0.66) did not differ significantly between groups. The estimated 10-year OS rate was significantly higher in the PN group (85.7%) compared to the RN group (73.3%) (p=0.003). PN was less likely to induce new-onset chronic kidney disease (CKD) and end-stage CKD compared with RN.
Conclusion
Our study suggests that patients treated with PN demonstrate a superior OS rate and postoperative renal function with analogous CSS and PFS rates compared with pair-matched patients treated with RN.

Citations

Citations to this article as recorded by

Prediction of clinically significant recurrence after partial nephrectomy. Data from the Cancer Registry of Norway with more than five years of follow-up
Ovidiu S. Barnoiu, Tom B. Johannesen, Lien M. Diep, Eskil S. Pedersen, Karin M. Hjelle, Christian Beisland
Scandinavian Journal of Urology.2024; 59: 1. CrossRef
Comparison of Oncological and Functional Outcomes of Radical Versus Partial Nephrectomy for cT1b Renal Cell Carcinoma: A Two-Centre, Matched Analysis
Luna van den Brink, Daniel L. van den Kroonenberg, Niels M. Graafland, Axel Bex, Harrie P. Beerlage, Jeroen R.A. van Moorselaar, Patricia J. Zondervan
Kidney Cancer.2024; 8(1): 51. CrossRef
Differences in the treatment patterns of small renal masses: A disaggregated analyses by race/ethnicity
Samuel Carbunaru, Jordan M. Rich, Yassamin Neshatvar, Katie Murray, Madhur Nayan
Urologic Oncology: Seminars and Original Investigations.2024; 42(12): 453.e1. CrossRef
Three-dimensional visualization techniques improve surgical Decision Making of robotic-assisted partial nephrectomy
Yuchao Wang, Qiliang Teng, Zhihong Dai, Chunyu Chen, Liren Zhang, Jiaxin Xie, Hao Wang, Zihan Xin, Sishan Chen, Yu Tai, Liang Wang, Bo Fan, Zhiyu Liu
Heliyon.2024; 10(21): e38806. CrossRef
Renal functional and cardiovascular outcomes of partial nephrectomy versus radical nephrectomy for renal tumors: a systematic review and meta-analysis
Mario Ochoa-Arvizo, Mariano García-Campa, Karla M. Santos-Santillana, Tobias Klatte, Luis R. García-Chairez, Alejandro D. González-Colmenero, Rigoberto Pallares-Méndez, Daniel E. Cervantes-Miranda, Hiram H. Plata-Huerta, Rene- Rodriguez-Gutierrez, Adrián
Urologic Oncology: Seminars and Original Investigations.2023; 41(3): 113. CrossRef
Frequency of Benign Lesions in Radiologically Presumed Renal Cell Carcinoma Taking Histopathology as Gold Standard
Ayesha Khan, Asad Shahzad Hassan, Naseem Akhtar, Rashid Ali, Rehan Mohsin, Altaf Hashmi, Nazish Mughal
Pakistan Journal of Health Sciences.2023; : 51. CrossRef
Laparoscopic partial versus radical nephrectomy for localized renal cell carcinoma over 4 cm
Zi-Jun Sun, Feng Liu, Hai-Bin Wei, Da-Hong Zhang
Journal of Cancer Research and Clinical Oncology.2023; 149(20): 17837. CrossRef
Long-term oncological results of surgical treatment of localized renal tumors
S. A. Rakul, K. V. Pozdnyakov, R. A. Eloev
Cancer Urology.2022; 17(4): 27. CrossRef
Near-Infrared Fluorescence Imaging of Renal Cell Carcinoma with ASP5354 in a Mouse Model for Intraoperative Guidance
Katsunori Teranishi
International Journal of Molecular Sciences.2022; 23(13): 7228. CrossRef
Comparison of oncologic outcomes between elective partial and radical nephrectomy in patients with renal cell carcinoma in CT1B stadium
Predrag Maric, Predrag Aleksic, Branko Kosevic, Mirko Jovanovic, Vladimir Bancevic, Dejan Simic, Nemanja Rancic
Vojnosanitetski pregled.2022; 79(6): 591. CrossRef
Machine learning-based prediction model for late recurrence after surgery in patients with renal cell carcinoma
Hyung Min Kim, Seok-Soo Byun, Jung Kwon Kim, Chang Wook Jeong, Cheol Kwak, Eu Chang Hwang, Seok Ho Kang, Jinsoo Chung, Yong-June Kim, Yun-Sok Ha, Sung-Hoo Hong
BMC Medical Informatics and Decision Making.2022;[Epub] CrossRef
Comparison of the oncological, perioperative and functional outcomes of partial nephrectomy versus radical nephrectomy for clinical T1b renal cell carcinoma: A systematic review and meta-analysis of retrospective studies
Yucong Zhang, Gongwei Long, Haojie Shang, Beichen Ding, Guoliang Sun, Wei Ouyang, Man Liu, Yuan Chen, Heng Li, Hua Xu, Zhangqun Ye
Asian Journal of Urology.2021; 8(1): 117. CrossRef
Machine Learning Approach to Predict the Probability of Recurrence of Renal Cell Carcinoma After Surgery: Prediction Model Development Study
HyungMin Kim, Sun Jung Lee, So Jin Park, In Young Choi, Sung-Hoo Hong
JMIR Medical Informatics.2021; 9(3): e25635. CrossRef
Long-term results of surgical treatment for stage cT1 kidney cancer
Sergey A. Rakul, Pavel N. Romashchenko, Kirill V. Pozdnyakov, Nikolay A. Maistrenko
Bulletin of the Russian Military Medical Academy.2021; 23(3): 133. CrossRef
Retroperitoneal laparoscopic partial versus radical nephrectomy for large (≥ 4 cm) and anatomically complex renal tumors: A propensity score matching study
Wen Deng, Zhengtao Zhou, Jian Zhong, Junhua Li, Xiaoqiang Liu, Luyao Chen, Jingyu Zhu, Bin Fu, Gongxian Wang
European Journal of Surgical Oncology.2020; 46(7): 1360. CrossRef
Synchronous sporadic bilateral multiple chromophobe renal cell carcinoma accompanied by a clear cell carcinoma and a cyst: A case report
Fan Yang, Zi-Chen Zhao, A-Jin Hu, Peng-Fei Sun, Bin Zhang, Ming-Chuan Yu, Juan Wang
World Journal of Clinical Cases.2020; 8(14): 3064. CrossRef
Peri‐operative and local control outcomes of robot‐assisted partial nephrectomy vs percutaneous cryoablation for renal masses: comparison after matching on radiological stage and renal score
Guillaume Fraisse, Loïc Colleter, Benoit Peyronnet, Zine‐Eddine Khene, Qusay Mandoorah, Yanish Soorojebally, Ali Bourgi, Alexandre De La Taille, Morgan Roupret, Eric De Kerviler, François Desgrandchamps, Karim Bensalah, Alexandra Masson‐Lecomte
BJU International.2019; 123(4): 632. CrossRef
Organ-sparing procedures in GU cancer: part 1—organ-sparing procedures in renal and adrenal tumors: a systematic review
Raouf Seyam, Mahmoud I. Khalil, Mohamed H. Kamel, Waleed M. Altaweel, Rodney Davis, Nabil K. Bissada
International Urology and Nephrology.2019; 51(3): 377. CrossRef
Comparison of the long-term follow-up and perioperative outcomes of partial nephrectomy and radical nephrectomy for 4 cm to 7 cm renal cell carcinoma: a systematic review and meta-analysis
Yu-Li Jiang, Cheng-Xia Peng, Heng-Zi Wang, Lu-Jie Qian
BMC Urology.2019;[Epub] CrossRef
Partial nephrectomy versus radical nephrectomy for cT2 or greater renal tumors: a systematic review and meta-analysis
Jingdong Li, Yanping Zhang, Zhihai Teng, Zhenwei Han
Minerva Urologica e Nefrologica.2019;[Epub] CrossRef
Analysis of survival for patients with chronic kidney disease primarily related to renal cancer surgery
Jitao Wu, Chalairat Suk‐Ouichai, Wen Dong, Elvis Caraballo Antonio, Ithaar H. Derweesh, Brian R. Lane, Sevag Demirjian, Jianbo Li, Steven C. Campbell
BJU International.2018; 121(1): 93. CrossRef
Oncologic Outcomes of Partial Nephrectomy for Stage T3a Renal Cell Cancer
Asaf Shvero, Ofer Nativ, Yasmin Abu-Ghanem, Dorit Zilberman, Bahouth Zaher, Max Levitt, Eddie Fridman, Orith Portnoy, Jacob Ramon, Zohar A. Dotan
Clinical Genitourinary Cancer.2018; 16(3): e613. CrossRef
External Validation of Contact Surface Area as a Predictor of Postoperative Renal Function in Patients Undergoing Partial Nephrectomy
Miki Haifler, Benjamin T. Ristau, Andrew M. Higgins, Marc C. Smaldone, Alexander Kutikov, Amnon Zisman, Robert G. Uzzo
Journal of Urology.2018; 199(3): 649. CrossRef
Survival outcomes in patients with large (≥7cm) clear cell renal cell carcinomas treated with nephron-sparing surgery versus radical nephrectomy: Results of a multicenter cohort with long-term follow-up
M. W. W. Janssen, J. Linxweiler, S. Terwey, S. Rugge, C.-H. Ohlmann, F. Becker, Ch. Thomas, A. Neisius, J. W. Thüroff, S. Siemer, M. Stöckle, F. C. Roos, Christian Schwentner
PLOS ONE.2018; 13(5): e0196427. CrossRef
Radiofrequency ablation versus cryoablation for T1b renal cell carcinoma: a multi-center study
Takaaki Hasegawa, Takashi Yamanaka, Hideo Gobara, Masaya Miyazaki, Haruyuki Takaki, Yozo Sato, Yoshitaka Inaba, Koichiro Yamakado
Japanese Journal of Radiology.2018; 36(9): 551. CrossRef
Néphrectomie partielle pour tumeur de plus de 7 cm : morbidité, résultats oncologiques et fonctionnels (UroCCR-7 study)
J. Rouffilange, A. Gobet, G. Capon, V. Comat, S. Lagabrielle, A. Guillaume, G. Robert, H. Bensadoun, J.-M. Ferrière, J.-C. Bernhard
Progrès en Urologie.2018; 28(12): 588. CrossRef
Partial Nephrectomy Versus Radical Nephrectomy for Clinical T1b and T2 Renal Tumors: A Systematic Review and Meta-analysis of Comparative Studies
Maria Carmen Mir, Ithaar Derweesh, Francesco Porpiglia, Homayoun Zargar, Alexandre Mottrie, Riccardo Autorino
European Urology.2017; 71(4): 606. CrossRef
Utilization trends and outcomes up to 3 months of open, laparoscopic, and robotic partial nephrectomy
Jamie S. Pak, Jason J. Lee, Khawaja Bilal, Mark Finkelstein, Michael A. Palese
Journal of Robotic Surgery.2017; 11(2): 223. CrossRef
Early surgical outcomes and oncological results of robot‐assisted partial nephrectomy: a multicentre study
Rajan Veeratterapillay, Sanjai K. Addla, Clare Jelley, John Bailie, David Rix, Steve Bromage, Neil Oakley, Robin Weston, Naeem A. Soomro
BJU International.2017; 120(4): 550. CrossRef
External validation of the Arterial Based Complexity (ABC) scoring system in renal tumors treated by minimally invasive partial nephrectomy
Liangyou Gu, Xin Ma, Hongzhao Li, Yuanxin Yao, Yongpeng Xie, Luyao Chen, Yu Gao, Xu Zhang
Journal of Surgical Oncology.2017; 116(4): 507. CrossRef
Partial nephrectomy vs. radical nephrectomy for renal tumors: A meta-analysis of renal function and cardiovascular outcomes
Zheng Wang, Ganggang Wang, Qinghua Xia, Zhenhua Shang, Xiao Yu, Muwen Wang, Xunbo Jin
Urologic Oncology: Seminars and Original Investigations.2016; 34(12): 533.e11. CrossRef
Novel Use of Folate-Targeted Intraoperative Fluorescence, OTL38, in Robot-Assisted Laparoscopic Partial Nephrectomy: Report of the First Three Cases
Cheuk Fan Shum, Clinton D. Bahler, Philip S. Low, Timothy L. Ratliff, Steven V. Kheyfets, Jay P. Natarajan, George E. Sandusky, Chandru P. Sundaram
Journal of Endourology Case Reports.2016; 2(1): 189. CrossRef
Recommandations en onco-urologie 2016-2018 du CCAFU : Cancer du rein
K. Bensalah, L. Albiges, J.-C. Bernhard, P. Bigot, T. Bodin, R. Boissier, J.-M. Corréas, P. Gimel, J.-A. Long, F.-X. Nouhaud, I. Ouzaïd, P. Paparel, N. Rioux-Leclercq, A. Méjean
Progrès en Urologie.2016; 27: S27. CrossRef

13,964 View
187 Download
35 Web of Science
33 Crossref

The Efficacy and Safety of Platinum/Vinorelbine as More Than Second-Line Chemotherapy for Advanced Non-small Cell Lung Cancer: Ik-Chan Song, Hyo-Jin Lee, Young-Jun Yang, Yoon-Seok Choi, Hye-Won Ryu, Myung-Won Lee, Ji Young Moon, Deog-Yeon Jo, Samyong Kim, Hwan-Jung Yun; Cancer Res Treat. 2015;47(4):638-644. Published online March 2, 2015; DOI: https://doi.org/10.4143/crt.2014.316

Abstract PDF PubReader ePub: Purpose
There is no regimen that is strongly recommended for more than second-line treatment. We investigated the efficacy and safety of platinum/vinorelbine as more than second-line treatment. Materials and Methods We selected patients with advanced non-small cell lung cancer (NSCLC) who received treatment with platinum/vinorelbine at Chungnam National University Hospital from August 2001 to December 2013. The primary end point was the response rate, and secondary end points were progression-free survival (PFS), overall survival (OS), and toxicity.
Results
Thirty-five patients were enrolled. Response rate was 22.9% (complete response, 0 patients [0%]; partial response, eight patients [22.9%]; stable disease, 10 patients [28.6%]; progressive disease, 14 patients [40.0%]). A significantly higher response rate was observed for patients who had responded to previous chemotherapy than for those who did not (34.8% [8/23] vs. 0% [0/12], p=0.020). The median PFS was 4 months (range, 1 to 21 months). Patients with adenocarcinoma and non-smokers had a significantly longer PFS than patients with non-adenocarcinoma and smokers (5 months vs. 2 months, p=0.007; 4.5 months vs. 2 months, p=0.046, respectively). The median OS was 10 months (range, 1 to 41 months). Patients with good performance status and non-smokers had a significantly longer OS than patients with poor performance status and smokers (14 months vs. 4 months, p=0.02; 18.5 months vs. 6 months, p=0.049, respectively). The main serious adverse event (grade 3 or 4) was neutropenia (15 events, 13.3%) in a total of 113 cycles. Conclusion Platinum/vinorelbine was effective as more than second-line chemotherapy, and the toxicity was tolerable, in patients with advanced NSCLC.

12,212 View
62 Download

Decision Based on Narrow Band Imaging Cystoscopy without a Referential Normal Standard Rather Increases Unnecessary Biopsy in Detection of Recurrent Bladder Urothelial Carcinoma Early after Intravesical Instillation: Phil Hyun Song, Seok Cho, Young Hwii Ko; Cancer Res Treat. 2016;48(1):273-280. Published online March 2, 2015; DOI: https://doi.org/10.4143/crt.2014.190

Abstract PDF PubReader ePub

Purpose
The purpose of this study was to calculate the operating characteristics of narrowband imaging (NBI) cystoscopy versus traditional white light cystoscopy (WLC) in common clinical scenarios involving suspicion of bladder urothelial carcinoma (UC). Materials and Methods Sixty-three consecutive patients initially underwent WLC and then NBI in a single session for evaluation of microscopic hematuria (group I, n=20), gross hematuria (group II, n=19), and follow-up for prior UC (group III, n=24), by an experienced urologist. All lesions that were abnormal in contrast with adjacent normal mucosa were diagnosed as positive and biopsied.
Results
Sixty-six biopsies from 47 patients were performed. Pathologic examination showed 17 cases of UC from 21 sites. While the overall sensitivity of NBI was similar to that of WLC (100% vs. 94.1%), the specificity of NBI was significantly lower than that of WLC (50% vs. 86.9%, p < 0.001), particularly in group III (38.9% vs. 88.9%, p=0.004). Based on identification by NBI only, 23 additional biopsies from 18 cases were performed for identification of one patient with UC, who belonged to group III. In this group, to identify this specific patient, 15 additional biopsies were performed from 10 patients. All seven cases with positive findings from NBI within 2 months after the last intravesical therapy were histologically proven as negative. Conclusion In evaluation for recurrence early after intravesical instillation, the decision based on NBI increased unnecessary biopsy in the absence of an established standard for judging NBI.

Citations

Citations to this article as recorded by

Comparison of narrow band imaging versus white light imaging in detecting non muscle invasive bladder cancer
Raghavendra RT, Amit Sharma, Deepak Biswal, Saryu Goel
Urologia Journal.2024; 91(2): 289. CrossRef
Advanced optical imaging techniques for bladder cancer detection and diagnosis: a systematic review
Marinka J. Remmelink, Yael Rip, Jakko A. Nieuwenhuijzen, Johannes C.F. Ket, Jorg R. Oddens, Theo M. de Reijke, Daniel M. de Bruin
BJU International.2024; 134(6): 890. CrossRef
Differentiation of Urothelial Carcinoma and Normal Bladder Tissues by Means of Fiber-Based ATR IR Spectroscopy
Rimantė Bandzevičiūtė, Gediminas Platkevičius, Justinas Čeponkus, Arūnas Želvys, Albertas Čekauskas, Valdas Šablinskas
Cancers.2023; 15(2): 499. CrossRef
Development and validation of a predictive model for the diagnosis of bladder tumors using narrow band imaging
Hao Liang, Qingya Yang, Yaozhong Zhang, Hui Sun, Qiang Fu, Tongxiang Diao, Jin Wang, Wei Huang, Yang Xu, Nan Ge, Xuewen Jiang, Shouzhen Chen, Yan Li, Bin Zhou, Peixin Li, Xiaoyi Zhang, Nianzhao Zhang, Benkang Shi, Jun Chen
Journal of Cancer Research and Clinical Oncology.2023; 149(17): 15867. CrossRef
Role of Macroscopic Image Enhancement in Diagnosis of Non-Muscle-Invasive Bladder Cancer: An Analytical Review
Prashant Motiram Mulawkar, Gyanendra Sharma, Ashwin Tamhankar, Utsav Shah, Rickaz Raheem
Frontiers in Surgery.2022;[Epub] CrossRef
Performance of Narrow Band Imaging (NBI) and Photodynamic Diagnosis (PDD) Fluorescence Imaging Compared to White Light Cystoscopy (WLC) in Detecting Non-Muscle Invasive Bladder Cancer: A Systematic Review and Lesion-Level Diagnostic Meta-Analysis
Giorgio I. Russo, Tamir N. Sholklapper, Andrea Cocci, Giuseppe Broggi, Rosario Caltabiano, Angela B. Smith, Yair Lotan, Giuseppe Morgia, Ashish M. Kamat, J. Alfred Witjes, Siamak Daneshmand, Mihir M. Desai, Indebir S. Gill, Giovanni E. Cacciamani
Cancers.2021; 13(17): 4378. CrossRef
Postoperative Recurrent Bladder Tumors Detection by Narrow-Band Imaging Cystoscopy
Won Tae Seo, Su Hwan Kang
The Korean Journal of Urological Oncology.2020; 18(3): 209. CrossRef
Blue-light cystoscopy and narrow-band imaging in bladder cancer management
Zhijiang Zang, Qinghui Wu, Edmund Chiong
Formosan Journal of Surgery.2019; 52(5): 155. CrossRef
Usefulness of narrow-band imaging in transurethral resection of bladder tumor: Early experience from a tertiary center in India
Kanuj Malik, Anand Raja, Sivakumar Mahalingam, L.S Ravishankar
South Asian Journal of Cancer.2019; 08(04): 226. CrossRef
Diagnostic performance of image technique based transurethral resection for non-muscle invasive bladder cancer: systematic review and diagnostic meta-analysis
Changhao Chen, Hao Huang, Yue Zhao, Hao Liu, Richard Sylvester, Tianxin Lin, Jian Huang
BMJ Open.2019; 9(10): e028173. CrossRef
Detection and recurrence rate of transurethral resection of bladder tumors by narrow-band imaging: Prospective, randomized comparison with white light cystoscopy
Seung Bin Kim, Sung Goo Yoon, Jonghyun Tae, Jae Yoon Kim, Ji Sung Shim, Sung Gu Kang, Jun Cheon, Jeong Gu Lee, Je Jong Kim, Seok Ho Kang
Investigative and Clinical Urology.2018; 59(2): 98. CrossRef
A meta-analysis of narrow band imaging for the diagnosis and therapeutic outcome of non-muscle invasive bladder cancer
YiQuan Xiong, JianDong Li, ShuJuan Ma, Jing Ge, LiZhi Zhou, Dongliang Li, Qing Chen, Robert Hurst
PLOS ONE.2017; 12(2): e0170819. CrossRef
Narrow band imaging-assisted transurethral resection reduces the recurrence risk of non-muscle invasive bladder cancer: A systematic review and meta-analysis
Weiting Kang, Zilian Cui, Qianqian Chen, Dong Zhang, Haiyang Zhang, Xunbo Jin
Oncotarget.2017; 8(14): 23880. CrossRef
Narrow band imaging for bladder cancer
Thomas Y. Hsueh, Allen W. Chiu
Asian Journal of Urology.2016; 3(3): 126. CrossRef

13,642 View
87 Download
14 Web of Science
14 Crossref

Incidence and Treatment Pattern of Extremity Soft Tissue Sarcoma in Korea, 2009-2011: A Nationwide Study Based on the Health Insurance Review and Assessment Service Database: Seungcheol Kang, Han-Soo Kim, Eun-Seok Choi, Ilkyu Han; Cancer Res Treat. 2015;47(4):575-582. Published online January 2, 2015; DOI: https://doi.org/10.4143/crt.2014.047

Abstract PDF PubReader ePub

Purpose
We conducted a nationwide study to assess the incidence and treatment patterns of extremity soft tissue sarcoma (STS) in South Korea.
Materials and Methods
The nationwide incidence and treatment patterns of extremity STS were assessed using two nationwide databases, the Korea National Cancer Incidence (KNCI) database and the Health Insurance Review and Assessment Service (HIRA) database.
Results
A total of 1,236 patients were newly diagnosed with extremity STS during the 3-year study period, from 2009 to 2011. The annual incidence of extremity STS in the Korean population was approximately 0.9 per 100,000 people with a male bias that increased with age and was especially pronounced amongst individuals aged > 80 years. Approximately 7% of patients did not receive any treatment, and surgical excision was performed for 85% of those who were treated.
Conclusion
This is the first nationwide study of the incidence and treatment patterns of extremity STS in Korea using two national databases (KNCI and HIRA), which include the entire Korean population. The results of this study may be useful for future planning and management of STS, at the national level.

Citations

Citations to this article as recorded by

Evaluation for Skin Cancer and Precancer in Patients With Vitiligo Treated With Long-term Narrowband UV-B Phototherapy
Jung Min Bae, Hyun Jeong Ju, Ro Woo Lee, Sang Ho Oh, Jeong Hyun Shin, Hee Young Kang, Ji Hun Park, Hee Jung Kim, Ki-Heon Jeong, Hee Jung Lee, SangHoon Lee, Dong Hyun Kim, Dong-Youn Lee, You Chan Kim, Gwang Seong Choi, Ki-Ho Kim, Chul Jong Park, Chong Won
JAMA Dermatology.2020; 156(5): 529. CrossRef
Incidence of soft tissue sarcoma in Taiwan: A nationwide population-based study (2007–2013)
Giun-Yi Hung, Jiun-Lin Horng, Paul Chih-Hsueh Chen, Li-Yih Lin, Jinn-Yang Chen, Pei-Hung Chuang, Ta-Chung Chao, Chueh-Chuan Yen
Cancer Epidemiology.2019; 60: 185. CrossRef
Molecular changes in solitary fibrous tumor progression
Hyung Kyu Park, Dan Bi Yu, Minjung Sung, Ensel Oh, Mingi Kim, Ji-Young Song, Mi-Sook Lee, Kyungsoo Jung, Ka-Won Noh, Sungbin An, Kyoung Song, Do-Hyun Nam, Yu Jin Kim, Yoon-La Choi
Journal of Molecular Medicine.2019; 97(10): 1413. CrossRef
Characteristics and Treatment Patterns of Patients with Advanced Soft Tissue Sarcoma in Korea
Hyo Song Kim, Chung Mo Nam, Suk-Yong Jang, Sun Kyu Choi, Minkyung Han, Seonmin Kim, Maria Victoria Moneta, Sae Young Lee, Jae Min Cho, Diego Novick, Sun Young Rha
Cancer Research and Treatment.2019; 51(4): 1380. CrossRef
Breast reconstruction statistics in Korea from the Big Data Hub of the Health Insurance Review and Assessment Service
Jae-Won Kim, Jun-Ho Lee, Tae-Gon Kim, Yong-Ha Kim, Kyu Jin Chung
Archives of Plastic Surgery.2018; 45(05): 441. CrossRef
Clinical research using medical big data
Geum Joon Cho
Anesthesia and Pain Medicine.2017; 12(1): 9. CrossRef

12,541 View
129 Download
10 Web of Science
6 Crossref

Which Patients Should We Follow up beyond 5 Years after Definitive Therapy for Localized Renal Cell Carcinoma?: Sang Hyub Lee, Hee Seo Son, Seok Cho, Sang Jin Kim, Dae Seon Yoo, Seok Ho Kang, Sung Yul Park, Jinsung Park, Sung-Goo Chang, Seung Hyun Jeon; Cancer Res Treat. 2015;47(3):489-494. Published online November 17, 2014; DOI: https://doi.org/10.4143/crt.2014.013

Abstract PDF PubReader ePub

Purpose
Up to 10% of recurrences develop beyond 5 years after curative treatment of localized renal cell carcinoma (RCC). Clinicopathologic features were evaluated to determine which factors are associated with late recurrence.
Materials and Methods
A total of 753 patients were diagnosed with localized RCC from January 2000 to June 2008. We enrolled 225 patients who were treated surgically and had a minimal recurrence-free survival of 60 months. Patients who had recurrence beyond 5 years after nephrectomy were defined as the late recurrence group and the remaining patients as the recurrence-free group. Multivariate logistic regression analyses and the Cox proportional hazard model were used for determination of features associated with late recurrence.
Results
In multivariate analyses, age older than 60 (p=0.030), Fuhrman grade ≥ 3 (p=0.042), and pT stage ≥ pT2 (p=0.010) showed statistical association with late recurrence. The Cox proportional hazard model showed significant differences in recurrence-free survival when we classified the patients based on pT2 (p=0.007) and on patient age ≥ 60 years (p=0.039).
Conclusion
Patient age greater than 60 years, Fuhrman grade ≥ 3, and tumor stage ≥ pT2 are independent risk factors of recurrence more than 5 years after surgery in patients with RCC. Therefore, close lifelong follow-up is recommended for patients with these risk factors.

Citations

Citations to this article as recorded by

Comparison of the Efficacy of Percutaneous Microwave Ablation Therapy versus Laparoscopic Partial Nephrectomy for Early-Stage Renal Tumors
Osman Kula, Yeliz Ateş, Hakkı Mete Çek, Atınç Tozsin, Burak Günay, Burak Akgül, Selçuk Korkmaz, Gökhan Karataş, Serdar Solak, Fethi Emre Ustabaşıoğlu, Ersan Arda
Diagnostics.2024; 14(14): 1574. CrossRef
Machine Learning Approach to Predict the Probability of Recurrence of Renal Cell Carcinoma After Surgery: Prediction Model Development Study
HyungMin Kim, Sun Jung Lee, So Jin Park, In Young Choi, Sung-Hoo Hong
JMIR Medical Informatics.2021; 9(3): e25635. CrossRef
Risk‐adjusted proposal for >60 months follow up after surgical treatment of organ‐confined renal cell carcinoma according to life expectancy
Sebastian K Frees, Mohammed M Kamal, Sebastian Nestler, Patrick MF Levien, Samir Bidnur, Walburgis Brenner, Christian Thomas, Wolfgang Jaeger, Joachim W Thüroff, Frederik C Roos
International Journal of Urology.2019; 26(3): 385. CrossRef
Partial nephrectomy versus ablative techniques for small renal masses: a systematic review and network meta-analysis
Johannes Uhlig, Arne Strauss, Gerta Rücker, Ali Seif Amir Hosseini, Joachim Lotz, Lutz Trojan, Hyun S. Kim, Annemarie Uhlig
European Radiology.2019; 29(3): 1293. CrossRef

13,830 View
82 Download
6 Web of Science
4 Crossref

Diagnostic and Prognostic Implications of Spine Magnetic Resonance Imaging at Diagnosis in Patients with Multiple Myeloma: Ik-Chan Song, Ji-Na Kim, Yoon-Seok Choi, Haewon Ryu, Myung-Won Lee, Hyo-Jin Lee, Hwan-Jung Yun, Samyong Kim, Soon Tae Kwon, Deog-Yeon Jo; Cancer Res Treat. 2015;47(3):465-472. Published online November 3, 2014; DOI: https://doi.org/10.4143/crt.2014.010

Abstract PDF PubReader ePub

Purpose
The aim of this study is to determine the diagnostic and prognostic role of baseline spinal magnetic resonance imaging (MRI) in patients with multiple myeloma.
Materials and Methods
We enrolled patients newly diagnosed with multiple myeloma from 2004-2011 at a single center. Abnormal MRI findings that were not detected in radiographs have been analyzed and categorized as malignant compression fractures or extramedullary plasmacytoma. The bone marrow (BM) infiltration patterns on MRI have been classified into five categories.
Results
A total of 113 patients with a median age of 65 years (range, 40 to 89 years) were enrolled in the study. Malignant compression fractures not detected in the bone survey were found in 26 patients (23.0%), including three patients (2.6%) with no related symptoms or signs. Extramedullary plasmacytoma was detected in 22 patients (19.5%), including 15 (13.3%) with epidural extension of the tumor. Of these 22 patients, 11 (50.0%) had no relevant symptoms or signs. The presence of malignant compression fractures did not influence overall survival; whereas non-epidural extramedullary plasmacytoma was associated with poor overall survival in the multivariate analysis (hazard ratio, 3.205; 95% confidence interval [CI], 1.430 to 9.845; p=0.042). During the follow-up for a median of 21 months (range, 1 to 91 months), overall survival with the mixed BM infiltrative pattern (median, 24.0 months; 95% CI, 22.9 to 25.1 months) was shorter than those with other patterns (median 56 months; 95% CI, 48.9 to 63.1 months; p=0.030).
Conclusion
These results indicate that spine MRI at the time of diagnosis is useful for detecting skeletal lesions and predicting the prognosis in patients with multiple myeloma.

Citations

Citations to this article as recorded by

Prognostic significance of extramedullary disease (EMD) detected on pre-transplant 18F-FDG PET/CT in patients with multiple myeloma: Results of PIPET-M trial
Uday Yanamandra, Arun Kumar Reddy Gorla, Kanhaiyalal Agrawal, Bhagwant Rai Mittal, Gaurav Prakash, Alka Rani Khadwal, Neelam Varma, Subhash Varma, Pankaj Malhotra
Medical Journal Armed Forces India.2023; 79(6): 672. CrossRef
Clinical impact of spine magnetic resonance imaging as a valuable prognostic tool for patients with multiple myeloma: a retrospective study
Jung Min Lee, Hee Jeong Cho, Joon-Ho Moon, Sang Kyun Sohn, Byunggeon Park, Dong Won Baek
Journal of Yeungnam Medical Science.2022; 39(4): 300. CrossRef
Diagnostic value of whole-body ultra-low dose computed tomography in comparison with spinal magnetic resonance imaging in the assessment of disease in multiple myeloma
Davide Ippolito, Cammillo Talei Franzesi, Sara Spiga, Valeria Besostri, Sara Pezzati, Fausto Rossini, Sandro Sironi
British Journal of Haematology.2017; 177(3): 395. CrossRef
Automated “Bone Subtraction” Image Analysis Software Package for Improved and Faster CT Monitoring of Longitudinal Spine Involvement in Patients with Multiple Myeloma
Marius Horger, Hendrick Ditt, Shu Liao, Katja Weisel, Jan Fritz, Wolfgang M. Thaiss, Sascha Kaufmann, Konstantin Nikolaou, Christopher Kloth
Academic Radiology.2017; 24(5): 623. CrossRef
Multimodality imaging of osseous involvement In haematological malignancies
Abhishek R Keraliya, Katherine M Krajewski, Jyothi P Jagannathan, Atul B Shinagare, Marta Braschi-Amirfarzan, Sree H Tirumani, Nikhil H Ramaiya
The British Journal of Radiology.2016; 89(1059): 20150980. CrossRef
Risk Stratification in Multiple Myeloma
Melissa Gaik-Ming Ooi, Sanjay de Mel, Wee Joo Chng
Current Hematologic Malignancy Reports.2016; 11(2): 137. CrossRef
Temporomandibular joint involvement in patients with multiple myeloma—a retrospective study
W. Abboud, R. Yahalom, M. Leiba, G. Greenberg, N. Yarom
International Journal of Oral and Maxillofacial Surgery.2016; 45(12): 1545. CrossRef

18,635 View
125 Download
7 Web of Science
7 Crossref

Glucose Transporter-1 Expression in Squamous Cell Carcinoma of the Tongue: Yoon Seok Choi, Seok Jin Kim, Dae Sik Kim, Seh Jong Park, Yong Park, Hye Jin Shin, Kwang-Yoon Jung, Seung-Kuk Baek, Bong Kyung Shin, Jung Woo Choi, Byung Soo Kim, Sang Won Shin, Yeul Hong Kim, Jun Suk Kim; Cancer Res Treat. 2007;39(3):109-115. Published online September 30, 2007; DOI: https://doi.org/10.4143/crt.2007.39.3.109

Abstract PDF PubReader ePub

Purpose

Tumor cells are known to express hypoxia-related proteins such as glucose transporter-1 (Glut-1). These hypoxia-induced changes may allow tumor cells to survive under sustained hypoxic microenvironments, and the surviving tumor cell under hypoxia may develop a more aggressive phenotype and so result in a poor prognosis.

Materials and Methods

The Glut-1 expression was analyzed by immunohistochemistry, and its association with the prognosis was assessed in 60 patients with squamous cell carcinoma of the tongue.

Results

The Glut-1 expression was diffuse with a membranous pattern, and the median percentage of Glut-1 positive tumor cells was 60% (range: 0.0~90.0%). A high Glut-1 expression (the percentage of positive tumor cells ≥ the median value, 60%) was associated with the location of primary lesion, lymph node metastasis status and disease stage (p<0.05). The expression of Glut-1 was correlated with the Ki-67 expression (r=0.406, p=0.001). Microvessel density, as represented by CD31 staining, was also correlated with the Glut-1 expression although its significance is weak (r=0.267, p=0.039). On the univariate analysis, the group with a high Glut-1 expression showed poorer overall survival than the group with a low Glut-1 expression (p<0.05). However, the Glut-1 expression failed to show any independent prognostic significance on the multivariate analysis.

Conclusion

The expression of Glut-1 may be useful for predicting the prognosis and determining the treatment strategy for the management of squamous cell carcinoma of the tongue.

Citations

Citations to this article as recorded by

Study of expression of GLUT-1 in oral potentially malignant disorders and oral squamous cell carcinoma: An immuno-histochemical analysis
Shylaja K. Attur, Anil Patel, Kailash M. Attur
Journal of Oral and Maxillofacial Pathology.2024; 28(1): 70. CrossRef
Prognostic value of glycolysis markers in head and neck squamous cell carcinoma: a meta-analysis
Yanting Wang, Yuanyuan Li, Laibo Jiang, Xianyue Ren, Bin Cheng, Juan Xia
Aging.2021; 13(5): 7284. CrossRef
The Role of Glucose Transporters in Oral Squamous Cell Carcinoma
Heinrich Botha, Camile S. Farah, Kendrick Koo, Nicola Cirillo, Michael McCullough, Rita Paolini, Antonio Celentano
Biomolecules.2021; 11(8): 1070. CrossRef
Glut 1 in Cancer Cells and the Inhibitory Action of Resveratrol as A Potential Therapeutic Strategy
Angara Zambrano, Matías Molt, Elena Uribe, Mónica Salas
International Journal of Molecular Sciences.2019; 20(13): 3374. CrossRef
Can increased metabolic status be a grading tool for oral squamous cell carcinoma? A glucose transporter 1 immunoexpression study
Abikshyeet Panda, Alokenath Bandyopadhyay, Gouse Mohiddin, Malvika Raghuvanshi, SanjayKumar Sahoo, Lipsa Bhuyan
Nigerian Journal of Surgery.2019; 25(2): 203. CrossRef
Plumbagin‐mediating GLUT1 suppresses the growth of human tongue squamous cell carcinoma
S Na, J Zhang, X Zhou, A Tang, D Huang, Q Xu, D Xue, J Qiu
Oral Diseases.2018; 24(6): 920. CrossRef
Expression of GLUT-1 in oral squamous cell carcinoma in tobacco and non-tobacco users
Neha Azad, Malti Kumari Maurya, Meenakshi Kar, Madhu Mati Goel, Ajay Kumar Singh, Mala Sagar, Divya Mehrotra, Vijay Kumar
Journal of Oral Biology and Craniofacial Research.2016; 6(1): 25. CrossRef
Distribution of Hypoxia-Inducible Factor-1α and Glucose Transporter-1 in Human Tongue Cancers
Marcelo Gadelha Vasconcelos, Rodrigo Gadelha Vasconcelos, Denise Hélen Imaculada Pereira de Oliveira, Edilmar de Moura Santos, Leão Pereira Pinto, Éricka Janine Dantas da Silveira, Lélia Maria Guedes Queiroz
Journal of Oral and Maxillofacial Surgery.2015; 73(9): 1753. CrossRef
Expression of glucose transporters in cancers
Leszek Szablewski
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer.2013; 1835(2): 164. CrossRef
T-Type Ca2+Channels in Normal and Abnormal Brain Functions
Eunji Cheong, Hee-Sup Shin
Physiological Reviews.2013; 93(3): 961. CrossRef
Glucose uptake mediated by glucose transporter 1 is essential for early tooth morphogenesis and size determination of murine molars
Hiroko Ida-Yonemochi, Mitsushiro Nakatomi, Hidemitsu Harada, Hiroki Takata, Otto Baba, Hayato Ohshima
Developmental Biology.2012; 363(1): 52. CrossRef
Hypoxia-related protein expression and its clinicopathologic implication in carcinoma of unknown primary
Ja Seung Koo, Haeryoung Kim
Tumor Biology.2011; 32(5): 893. CrossRef

10,734 View
57 Download
12 Crossref

The Surgeon's Expertise-Outcome Relationship in Gastric Cancer Surgery: Wansik Yu, Young Kook Yun, Ilwoo Whang, Gyu Seok Choi; Cancer Res Treat. 2005;37(3):143-147. Published online June 30, 2005; DOI: https://doi.org/10.4143/crt.2005.37.3.143

Abstract PDF PubReader ePub

Purpose

The surgical caseload or duration of practice of a surgeon may influence the outcomes of gastric cancer surgery. This study aimed to clarify the surgical quality provided by specialized gastric cancer surgeons.

Materials and Methods

The postoperative courses of 1,877 patients who underwent surgery for gastric cancer were retrospectively reviewed. For classification of the surgeon's expertise, the number of yearly resections performed by, and consecutive years of practice of, the surgeons were used. The outcome measures used were the 30-day mortality and long-term survival.

Results

Surgical mortalities of patients who underwent surgery by a specialized surgeon and those by a general surgeon revealed no statistically significant difference. A significant difference in the five-year survival rates was found with surgeons with at least two consecutive years of practice compared to those with less than two years, when 50 or more cases had been conducted per year (63.9% and 59.7%; p=0.0380). In cases of four-years of consecutive practice, the five-year survival rate was significantly improved, even if only 10 cases were performed annually (64.9% and 58.3%; p=0.0023), although the best survival rate was found with surgeons that had performed 50 or more surgeries per year.

Conclusion

Improved survival rates, with acceptable surgical mortality, can be achieved for gastric cancer when the surgery is performed by a specialized surgeon. A specialized gastric cancer surgeon can be defined as one who has operated on more than 50 new cases per year, with 2 or more consecutive years of surgical practice.

Citations

Citations to this article as recorded by

Lymphadenectomy for Gastric Cancer
Jenny Hwang, Jacquelyn Carr
Surgical Clinics of North America.2025; 105(1): 47. CrossRef
Associations of Annual Hospital and Surgeon Volume with Patient Outcomes After Gastrectomy: A Systematic Review and Meta-analysis
Jiafu Ji, Leiyu Shi, Xiangji Ying, Xinpu Lu, Fei Shan
Annals of Surgical Oncology.2022; 29(13): 8276. CrossRef
Keratinocyte cancer with incidental perineural invasion: A registry analysis of management and 5‐year outcomes
Agnieszka Adams, Brian De’Ambrosis, Ben Panizza, Paul Belt, James Emmett, Tim Warren, David C. Whiteman
Australasian Journal of Dermatology.2020; 61(3): 226. CrossRef
Operation time as a simple indicator to predict the overcoming of the learning curve in gastric cancer surgery: a multicenter cohort study
Tae-Han Kim, Keun Won Ryu, Jun Ho Lee, Gyu-Seok Cho, Woo Jin Hyung, Chan-Young Kim, Min-Chan Kim, Seung Wan Ryu, Dong Woo Shin, Hyuk-Joon Lee
Gastric Cancer.2019; 22(5): 1069. CrossRef
Are treatment outcomes in gastric cancer associated with either hospital volume or surgeon volume?
Yosuke Mukai, Yukinori Kurokawa, Shuji Takiguchi, Masaki Mori, Yuichiro Doki
Annals of Gastroenterological Surgery.2017; 1(3): 186. CrossRef
Full robot-assisted gastrectomy: surgical technique and preliminary experience from a single center
Yolanda Quijano, Emilio Vicente, Benedetto Ielpo, Hipolito Duran, Eduardo Diaz, Isabel Fabra, Luis Malave, Valentina Ferri, Antonio Ferronetti, Carlos Plaza, Vito D’Andrea, Riccardo Caruso
Journal of Robotic Surgery.2016; 10(4): 297. CrossRef
The positive impact of surgeon specialization on survival for gastric cancer patients after surgery with curative intent
Yuexiang Liang, Liangliang Wu, Xiaona Wang, Xuewei Ding, Han Liang
Gastric Cancer.2015; 18(4): 859. CrossRef
Moderating Effect of Structural Complexity on the Relationship between Surgery Volume and in Hospital Mortality of Cancer Patients
Kyungil Youn
Health Policy and Management.2014; 24(4): 380. CrossRef
Robot-Assisted Gastrectomy With Lymph Node Dissection for Gastric Cancer
Jyewon Song, Sung Jin Oh, Wook Ho Kang, Woo Jin Hyung, Seung Ho Choi, Sung Hoon Noh
Annals of Surgery.2009; 249(6): 927. CrossRef

8,481 View
46 Download
9 Crossref

Impact of Neoadjuvant Chemotherapy on Postoperative Morbidity in Locally Advanced Cervical Carcinoma: Tae Sung Lee, Mi Suk Kim, Suk Bong Koh, Youn Seok Choi; Cancer Res Treat. 2002;34(3):186-190. Published online June 30, 2002; DOI: https://doi.org/10.4143/crt.2002.34.3.186

Abstract PDF

PURPOSE
The purpose of this study was to test the hypothesis that neoadjuvant chemotherapy (NACT) does not increase morbidity in patients undergoing radical hysterectomy with lymphadenectomy for locally advanced cervical cancer. MATERIALS AND METGODS: A retrospective study was undertaken of 140 patients with locally advanced cervical cancer (FIGO stage Ia to IIb) who underwent radical hysterectomy with lymphadenectomy by the same surgeon at the same hospital. Among the 140 patients, 39 received NACT followed by radical hysterectomy with pelvic lymphadenectomy (NACT group). This group received three cycles consisting of cisplatin 100 mg/m2/day on day 1 and 5-fluorouracil 1000 mg/m2/day from day 1 to 5. The NACT group was compared, in terms of intraoperative morbidity and postoperative morbidity, with the other 101 patients who underwent radical hysterectomy with lymphadenectomy but without chemotherapy (surgery-only group).
RESULTS
There were no significant differences in mean age, body weight or height between the two groups. The only significant difference was that the NACT patients had higher stages of cancer. The incidence of intraoperative morbidity did not differ between the NACT and surgery only patients. We considered the operation duration, amount of blood loss and need for transfusion as indicators of intraoperative morbidity. We could not find any significant differences in the duration of suprapubic catheterization, days of hemovac drainage, amount of drained hemovac fluid, days of hospitalization or postoperative febrile morbidity between the NACT and surgery-only groups. Patients in the surgery-only group had more postoperative complications (ureteral obstruction, intestinal obstruction, lymphocyst, lymphedema, and death) than the NACT group, although not to a statistically significant degree (P>0.05).
CONCLUSION
In this retrospective review, there was no evidence that NACT increased intraoperative or postoperative morbidity in patients with locally advanced cervical cancer. As this was a retrospective study, other prospective, randomized studies are needed to confirm these results.

Citations

Citations to this article as recorded by

Role of Pelvic Ultrasound in Predicting the Response to Neoadjuvant Chemotherapy in Locally Advanced Cervical Cancer
Giorgia Perniola, Giulia Paoni Saccone, Noemi Tonti, Federica Tanzi, Innocenza Palaia, Violante Di Donato, Federica Tomao, Ludovico Muzii, Giorgio Bogani, Ilaria Cuccu, Enrico Ciminello, Francesco Antonio Battaglia, Giusi Santangelo
Diagnostics.2025; 15(4): 463. CrossRef
The Role of 2D/3D Ultrasound to Assess the Response to Neoadjuvant Chemotherapy in Locally Advanced Cervical Cancer
Giorgia Perniola, Federica Tomao, Marialida Graziano, Innocenza Palaia, Margherita Fischetti, Francesca Lecce, Assunta Casorelli, Violante Di Donato, Antonella Giancotti, Francesco Antonio Battaglia, Ludovico Muzii, Pierluigi Benedetti Panici
Oncology.2020; 98(11): 807. CrossRef

4,530 View
20 Download
2 Crossref

Quantitative Analysis of Metastatic Lymph Nodes after Curative Surgery in Gastric Cancer: Wansik Yu, Yeon Sik Ji, Gyu Seok Choi, Ilwoo Whang, In Soo Suh; J Korean Cancer Assoc. 1997;29(1):62-68.

Abstract PDF: PURPOSE
A consecutive series of 710 patients who underwent curative gastrectomy for carcinoma was studied with a special reference to the number or frequency of lymph node metastasis and the patient's prognosis. MATERIAL AND METHODS: Survival rates were calculated by the Kaplan-Meier method, and the difference between each group was evaluated statistically by the log-rank method. Follow-up was obtained for 709 patients (99.9%).
RESULTS
According to the number of lymph nodal metastases, the five year survival rate for group 1 (1~3 positive nodes) was 50.9%; for group 2 (4~6 positive nodes), 56.7%; and for group 3 (more than 6 positive nodes), 12.0% (p<0.0001). According to the frequency of lymph node metastases, the five year survival rate for those with up to 25 per cent frequency of metastases was 47.5%; for those with up to 50 per cent frequency of metastases, 15.6%; and for those with greater than 50 per cent metastases, 6.3% (p<0.0001). According to the frequency of the regional lymph nodes (which include perigastric nodes along the lesser and greater curvatures, nodes located along the left gastric, common hepatic, splenic, and celiac arteries) metastasis, we categorized them as group 0 (N0: no metastasis), 1 (N1: metastasis in up to 25%), and 2 (N2: metastasis in greater than 25%).
CONCLUSION
This subdivision could be successfully applied to the clinical evaluation of gastric carcinoma (five year survival rate for N0, 86.9%; for N1, 49.0%; and for N2, 10.7% (p<0.0001)) without difficulty in dividing certain lymph nodes into the correct location.

2,576 View
12 Download

Engraftment Syndrome after Peripheral Blood Stem Cell Auto - transplantation - A report of the case -: Bong Seok Choi, Yeo Hyeon Ahn, You Jeong, Ik Joo Chung, Hyeoung Joon Kim, Hoon Kook, Tai Ju Hwang; J Korean Cancer Assoc. 1996;28(5):921-927.

Abstract PDF: We experienced two cases of engraftment syndrome (ES) in a 17-year-old boy with malignant lymphoma and in a 53-year-old female patient with small cell lung cancer following peripheral blood stem cell auto-transplantation. ES is a reproducible clinical constellation of fever, skin rash, capillary leak and pulmonary infiltrates without infection, characteristically observed during engraftment in patients undergoing autoglogous bone marrow or peripheral stem cell transplantation. The incidence of ES has been reported to be about 60%. The early recognition of ES followed by administration of steroids might obviate the unnecessary use of antibiotics and help improve clinical manifestaions in the critical post-transplant neutropenic period.

2,470 View
16 Download

First
Prev
Page of 1
Next
Last

Search